AZTR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Azitra Inc (AZTR) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock has weak financial performance, no significant trading trends, and lacks strong positive catalysts. While the technical indicators show some neutral signals, the overall sentiment and financial health of the company do not support a confident buy decision.
The MACD is slightly positive, indicating mild bullish momentum. However, the RSI is neutral at 45.379, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels (R1: 0.197) and close to its pivot point (0.178), suggesting limited upside potential in the short term.
Azitra has initiated promising clinical trials for its ATR-04 program and Netherton syndrome treatment, with positive safety data reported. The company also exceeded EPS expectations in its latest report.
The company canceled its special stockholder meeting due to a lack of quorum, which could indicate governance or operational issues. Financial performance is weak, with declining net income (-6.67% YoY) and EPS (-90.38% YoY). The company has limited cash reserves ($2.1 million), which raises concerns about its ability to sustain operations.
In Q4 2025, Azitra reported no revenue growth, a net income loss of -$2.23 million (-6.67% YoY), and a significant EPS decline (-90.38% YoY). Gross margin dropped to 0, reflecting poor financial health.
No analyst rating or price target changes are available for Azitra Inc.
